ProCE Banner Activity

Répondre aux questions clés concernant le traitement optimal des patients atteints de leucémie lymphoïde chronique récurrente ou réfractaire

Clinical Thought

Dans le cadre de cette activité, des experts abordent des questions clés concernant le traitement des patients atteints de leucémie lymphoïde chronique (LLC) récurrente ou réfractaire (R/R), comme discuté lors d’une table ronde en direct. Ces réponses fournissent des informations exploitables et applicables que les professionnels de la santé très sollicités peuvent utiliser en clinique.

Released: December 23, 2024

Expiration: December 22, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Department of Hematology and Oncology
University Hospital of Cologne
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

Alessandra Tedeschi, MD

Medical Doctor
Department of Hematology
Niguarda Cancer Center Milano
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson.